201. Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma.
- Author
-
Xu, Jian‐ping, Hao, Xue‐zhi, Zhang, Xiang‐ru, Yang, Sheng, and Shi, Yuan‐kai
- Subjects
- *
COMBINATION drug therapy , *CISPLATIN , *CYTOLOGICAL techniques , *DRUG side effects , *LIVER diseases , *NEUTROPENIA , *PACLITAXEL , *THROMBOCYTOPENIA , *THYMOMA , *CARBOPLATIN , *TUMOR grading , *PHARMACODYNAMICS - Abstract
This study aimed to assess the efficacy and safety of a combination of paclitaxel and cisplatin/carboplatin for the treatment of advanced thymic carcinoma. Thirty-seven patients (23 men and 14 women, median age 47 years, performance status score ≤2) with pathologically or cytologically diagnosed advanced thymic carcinoma were recruited. Patients received 175 mg/m2 paclitaxel on day 1 and 75 mg/m2 cisplatin or 300 mg/m2 carboplatin on day 2 of a 21 day cycle for at least two cycles to evaluate efficacy and adverse events. No complete response ( CR) was observed; 11 patients had a partial response ( PR), 16 patients had no change ( NC), and 10 had progressive disease, resulting in an overall response rate of 29.7%, a stable rate of 43.2%, and a disease control rate ( CR + PR + NC) of 72.9%. Grade I/ II and III/ IV neutropenia were observed in 21 (56.7%) and 13 (35.1%) patients, respectively. Four (10.8%) patients developed grade I/ II thrombocytopenia. Grade I/ II and III/ IV nausea and vomiting were observed in 19 (51.2%) and five (13.5%) patients, respectively. Grade I/ II liver dysfunction was observed in seven (18.9%) patients. Two patients with grade III liver dysfunction recovered after hepatoprotective treatment. The combination of paclitaxel and platinum was effective and well tolerated in patients with advanced thymic carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF